| CNS |
|
| Brain tumor |
Temozolamide (alkylating agent) |
| Carcinomatous meningitis |
MTX |
| Retinoblastoma |
CEV: Cisplatin, etoposide, vincristine |
| Head & neck cancer |
Cisplatin |
| Lung cancer |
Cisplatin |
| Tysone kinase inhibitor (After ECG): Aftinib, erlotinib, ceritinib, geftinib |
|
| Endocrine tumors |
|
| Medullary thyroid Ca |
Tyrosine kinase inhibitor: Vandetanib |
| Malignant pheochromocytoma |
Averbuch’s protocol (VCD): Vincristine + cyclophosphamide + decarbazine |
| Orthopedic cancer |
|
| Osteosarcoma |
High-dose MTX + leucovorin rescue |
| Breast cancer |
ER(+), premenopausal: Tamoxifen (SERM) |
| ER(+), post-menopausal: Aromatase inhibitor (letrozole) (If no response: Fluvestrant) |
|
| HER2(+): Transtuzumab (If no response: Lapatinib) |
|
| Triple (-): Cytotoxic agents (cyclophosphamide, taxanes, eribulin, ixobepilone) |
|
| GI |
|
| Esophageal & gastric Ca |
ECF: Epirubicin + Cisplatin + 5-FU |
| GIST |
Tyrosine kinase inhibitor (SIR): Sunitinib, imatinib, regorafenib |
| Small intestine adenocarcinoma |
5-FU |
| Colorectal Ca |
FOLFOX: 5-FU (DOC) + oxaliplatin + leucovorin (enhances effect of 5-FU) + folinic acid |
| Tryrosine kinase inhibitor: Regorafenib |
|
| Anal Ca |
Nigro Regimen: |
| Chemoradiation [5-FU (DOC) + Mitomycin C (topical)] + Radiation |
|
| Pancreatic Ca |
DOC: Gemcitabine |
| Alternative: FOLFIRINOX (FOLFOX + irinotecan) |
|
| HCC |
Tyrosine kinase inhibitrs: Sorafeneb (DOC) |
| Urogenital cancers |
|
| Bladder cancer |
Cisplatin (DOC) + gemcitabine |
| RCC |
Tyrosine kinase inhibitrs (PASS): Pazopanib, axitinib, sorafenib, sunitinib |
| Ovarian Ca |
Cisplatin (DOC) + taxane (paclitaxel) |
| Cervical Ca |
Cisplatin (DOC) |
| Testicular Ca |
BEP: Bleomycin + etoposide + platinum compound (cisplatin) |
| Gestational trophoblastic neoplasia (GTN) |
Low-risk GTN: Methotrexate (MTX) |
| High-risk GTN (EMA/CO): Etoposide + MTX + dactinomycin alternating with cyclophosphamide + oncovin (vincristine) |
|
| Lymphoma |
|
| Hodgkin |
ABVD: Adriamycin (doxorubicin) + bleomycin + vinblastine + dacarbazine |
| Low grade NHL |
FCR: Fludarabine + cyclophosphamide + rituximab |
| High grade NHL |
CHOP-R: Cyclophosphamide + hydroxydonorubicin + oncovin (vincristine) + presdnisolone + rituximab |
| Leukemia |
|
| AML |
Cytarabine + donorubicin/idarubicin |
| ALL |
VPAD: Vincristine + prednisone + asparaginase + donorubicin |
| CLL |
FCR: Fludarabine + cyclophosphamide + rituximab |
| CML |
BCR-ABL tyrosine kinase inhibitors (IND): Imatinib (DOC), nilotinib, dasatinib, bosutinib |
| Multi-tyrosine kinase inhibitor resistant CML: Umacitael |
|
| Hairy cell leukemia |
Purine analogs: Cladribine (DOC), pentostatin |
| Interferon-alpha |
|
| Chemotherapy-refractory patients: Vemurafenib (BRAF inhibitor) |
|
| Skin cancer |
|
| Malignant melanoma |
Tyrosine kinase inbibitor (DVT): Dabrefenib, vemurafenib, trameltenib |